Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of the combination of Avastin and metronomic temozolomide in
recurrent malignant glioma patients. The primary objective will be to determine the efficacy
of Avastin (bevacizumab) and metronomic temozolomide in malignant glioma patients. The
secondary objective will be to determine the safety of Avastin, 10 mg/kg every other week, in
combination with metronomic temozolomide in terms of progression-free survival.